Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights April 14, 2025
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights April 10, 2025
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights April 10, 2025